Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients

Journal of Clinical Psychopharmacology

Volumn 19, Issue 6, 1999, Pages 494-499

  Carrillo, Juan A ^a   Ramos, Sara I ^a   Herraiz, Angustias G ^b   Llerena, Adrian ^a   Agundez, Jose A G ^a   Berecz, Roland ^a   Duran, Marisol ^a   Benítez, Julio ^a  

^a UNIVERSITY OF EXTREMADURA   (Spain)

^b Psychiat Hosp Adolfo Diaz Ambrona   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; DRUG METABOLITE; FLUVOXAMINE; SEROTONIN UPTAKE INHIBITOR; THIORIDAZINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MENTAL DISEASE; PATIENT MONITORING; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; SCHIZOPHRENIA;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; CYTOCHROME P-450 CYP2D6; DRUG INTERACTIONS; FLUVOXAMINE; HUMANS; MALE; MESORIDAZINE; MIDDLE AGED; SCHIZOPHRENIA; SEROTONIN UPTAKE INHIBITORS; THIORIDAZINE;

EID: 0032699804     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199912000-00002     Document Type: Article

References (49)

1. Baumann P. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet 1996;31:444-69.
2. Wagner W, Vause EW. Fluvoxamine: a review of global drug-drug interaction data. Clin Pharmacokinet 1995;29:26-32.
3. Sproule BA, Naranjo CA, Bremner KE, Hassan PC. Selective serotonin reuptake inhibitors and CNS drug interactions. Clin Pharmacokinet 1997;33:454-71.
4. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992;34:262-5.
5. Skjelbo E, Brøsen K. Inhibitors of imipramine metabolism by human liver microsomes. Br J Clin Pharmacol 1992;34:256-61.
6. Jeppessen U, Gram LF, Vistisen K, Loft S, Poulsen HE, Brøsen K. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol 1996;51:73-8.
7. Spina E, Campo GM, Avenoso A, Pollicino MA, Caputi AP. Interaction between fluvoxamine and imipramine/desipramine in four patients. Ther Drug Monit 1992;14:194-6.
8. Spina E, Pollicino AM, Avenoso A, Campo GM, Caputi AP. Fluvoxamine-induced alterations in plasma concentrations of imipramine and desipramine in depressed patients. Int J Clin Pharmacol Res 1993;13:167-71.
9. Xu ZH, Xie HG, Zhou HH. In vivo inhibition of CYP2C19 but not CYP2D6 by fluvoxamine. Br J Clin Pharmacol 1996;42:518-21.
10. Brøsen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 1993;45:1211-4.
11. Rasmussen BB, Maenpaa J, Pelkonen O, Loft S, Poulsen HE, Lykkesfeldt J, Brøsen K. Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine. Br J Clin Pharmacol 1995;39:151-9.
12. Vandel S, Bertschy G, Baumann P, Bouquet S, Bonin B, Francois T, Sechter D, Bizouard P. Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. Pharmacol Res 1995;31:347-53.
13. Jeppesen U, Rasmussen BB, Brøsen K. Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide. Clin Pharmacol Ther 1997;62:279-86.
14. Perucca E, Gatti G, Cipolla G, Spina E, Barel S, Soback S, Gips M, Bialer M. Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers. Clin Pharmacol Ther 1994;56:471-6.
15. Lemoine A, Gautier JC, Azoulay D, Kiffel L, Belloc C, Guengerich FP, Maurel P, Beaune P, Leroux JP. Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P450 3A4 in human liver. Mol Pharmacol 1993;43:827-32.
16. Bertschy G, Vandel S, Vandel B, Allers G, Volmat R. Fluvoxamine-tricyclic antidepressant interaction. Eur J Clin Pharmacol 1991; 40:119-20.
17. Flockhart DA. Drug interactions and the cytochrome P450 system. The role of cytochrome P450 2C19. Clin Pharmacokinet 1995;29[suppl 1]:45-52.
18. Dahl SG. Active metabolites of neuroleptic drugs: possible contribution to therapeutic and toxic effects. Ther Drug Monit 1982; 4:33-40.
19. Hale PW, Poklis A. Cardiotoxicity of thioridazine and two stereoisomeric forms of thioridazine 5-sulfoxide in the isolated perfused rat heart. Toxicol Appl Pharmacol 1986;86:44-55.
20. von Bahr C, Movin G, Nordin C, Liden A, Hammarlund-Udenaes M, Hedberg A, Ring H, Sjöqvist F. Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype. Clin Pharmacol Ther 1991;49:234-40.
21. Meyer JW, Woggon B, Baumann P, Meyer UA. Clinical implications of slow sulphoxidation of thioridazine in a poor metabolizer of the debrisoquine type. Eur J Clin Pharmacol 1990;39:613-4.
22. Eap CB, Guentert TW, Schaublin Loidl M, Stabl M, Koeb L, Powell K Baumann P. Plasma levels of the enantiomers of thioridazine, thioridazine 2-sulfoxide, thioridazine 2-sulfone, and thioridazine 5-sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin. Clin Pharmacol Ther 1996;59:322-31.
23. Overall JE, Gorham DR. Brief Psychiatric Rating Scale. Psychol Rep 1962;10:799-812.
24. Lingjërde O, Ahlfors UG, Bech P, Dencker SJ, Eigen K. The UKU side effect rating scale. Acta Psychiatr Scand 1987;76:11-100.
25. Neitzel HA. A routine method for the establishment of permanent growing of lymphoblastoid cell lines. Hum Genet 1986;73:320-2.
26. Heim M, Meyer UA. Genetic polymorphism of debrisoquine oxidation: analysis of mutant alleles of CYP2D6 by restriction fragment analysis and by allele specific amplification. Methods Enzymol 1991;206:173-83.
27. Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjöqvist F, Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 1993;90: 11825-9.
28. Tyndale RF, Aoyama T, Broly F, Matsunaga T, Inaba T, Kalow W, Gelboin HV, Meyer UA, Gonzalez FJ. Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotype. Pharmacogenetics 1991;1:26-32.
29. Agúndez JAG, Martínez C, Ledesma MC, Ladona MG, Ladero JM, Benítez J. Genetic basis for differences in debrisoquin polymorphism between a Spanish and other white populations. Clin Pharmacol Ther 1994;55:412-7.
30. Eap CB, Koeb L, Baumann P. Artifacts in the analysis of thioridazine and other neuroleptics. J Pharm Biomed Anal 1993;11: 451-7.
31. Plasky P. Antidepressant usage in schizophrenia. Schizophr Bull 1991;17:649-57.
32. Härtter S, Wetzel H, Hammes E, Torkzadeh M, Hiemke C. Nonlinear pharmacokinetics of fluvoxamine and gender differences. Ther Drug Monit 1998;20:446-9.
33. Spigset O, Granberg K, Hagg S, Soderstrom E, Dahlqvist R. Nonlinear fluvoxamine disposition. Br J Clin Pharmacol 1998;45: 257-63.
34. Carrillo JA, Dahl ML, Svensson JO, Alm C, Rodriguez I, Bertilsson L. Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity. Clin Pharmacol Ther 1996;60:183-90.
35. Spigset O, Granberg K, Hagg S, Norstrom A, Dahlqvist R. Relationship between fluvoxamine pharmacokinetics and CYP2D6/ CYP2C19 phenotype polymorphisms. Eur J Clin Pharmacol 1997;52:129-33.
36. Yasui N, Otani K, Kaneko S, Ohkubo T, Osanai T, Ishida M, Mihara K, Kondo T, Sugawara K, Fukushima Y. Inhibition of trazodone metabolism by thioridazine in humans. Ther Drug Monit 1995;-17:333-5.
37. Yasui N, Tybring G, Otani K, Mihara K, Suzuki A, Svensson JO, Kaneko S. Effects of thioridazine, an inhibitor of CYP2D6, on the steady-state plasma concentrations of the enantiomers of mianserin and its active metabolite, desmethylmianserin, in depressed Japanese patients. Pharmacogenetics 1997;7:369-74.
38. Venkatakrishnan K, Greenblatt DJ, von Moltke LL, Schmider J, Harmatz JS, Shader RI. Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro: dominance of CYP 2C19 and 3A4. J Clin Pharmacol 1998;38:112-21.
39. Hiemke C, Weigmann H, Härtter S, Dahmen N, Wetzel H, Müller H. Elevated levels of clozapine in serum after addition of fluvoxamine. J Clin Psychopharmacol 1994;14:279-81.
40. Jeppesen U, Loft S, Poulsen HE, Brøsen K. A fluvoxamine-caffeine interaction study. Pharmacogenetics 1996;6:213-22.
41. Jerling M, Lindstrom L, Bondesson U, Bertilsson L. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 1994;16:368-74.
42. Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. Clin Pharmacokinet 1997;32:1-21.
43. Papadopoulos AS, Crammer JL, Cowan DA. Phenolic metabolites of thioridazine in man. Xenobiotica 1985;15:309-16.
44. Lin G, Hawes EM, McKay G, Korchinski ED, Midha KK. Metabolism of piperidine-type phenothiazine antipsychotic agents. IV. Thioridazine in dog, man and rat. Xenobiotica 1993;23:1059-74.
45. Maynard GL, Soni P. Thioridazine interferences with imipramine metabolism and measurement. Ther Drug Monit 1996; 18:729-31.
46. Eap CB, Koeb L, Powell K, Baumann P. Determination of the enantiomers of thioridazine, thioridazine 2-sulfone, and of the isomeric pairs of thioridazine 2-sulfoxide and thioridazine 5-sulfoxide in human plasma. J Chromatogr B Biomed Appl 1995;669: 271-9.
47. Hollister LE, Kosik JC. Sudden death during treatment with phenothiazine derivatives. JAMA 1965;192:1035-8.
48. Kelly HQ, Fay JE, Laverty FG. Thioridazine hydrochloride (Mellaril): its effect on the electrocardiogram and a report on two fatalities with electrographic abnormalities. Can Med Assoc J 1963; 89:546-54.
49. Hartigan-Go K, Bateman DN, Nyberg G, Martensson E, Thomas SH. Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans. Clin Pharmacol Ther 1996; 60:543-53.